[go: up one dir, main page]

NO20074277L - Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer - Google Patents

Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer

Info

Publication number
NO20074277L
NO20074277L NO20074277A NO20074277A NO20074277L NO 20074277 L NO20074277 L NO 20074277L NO 20074277 A NO20074277 A NO 20074277A NO 20074277 A NO20074277 A NO 20074277A NO 20074277 L NO20074277 L NO 20074277L
Authority
NO
Norway
Prior art keywords
liver
kinnolin
compounds
receptor modulators
modulators
Prior art date
Application number
NO20074277A
Other languages
English (en)
Inventor
Michael David Collini
Baihua Hu
Rayomand J Unwalla
Jay E Wrobel
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20074277L publication Critical patent/NO20074277L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår generelt kinnolin-baserte modulatorer av Lever X reseptorer (LXRs) og relaterte metoder.
NO20074277A 2005-03-01 2007-08-22 Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer NO20074277L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65729605P 2005-03-01 2005-03-01
PCT/US2006/007224 WO2006094034A1 (en) 2005-03-01 2006-03-01 Cinnoline compounds and their use as liver x receptor modilators

Publications (1)

Publication Number Publication Date
NO20074277L true NO20074277L (no) 2007-11-23

Family

ID=36589080

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074277A NO20074277L (no) 2005-03-01 2007-08-22 Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer

Country Status (16)

Country Link
US (1) US7700595B2 (no)
EP (1) EP1853566A1 (no)
JP (1) JP2008531709A (no)
KR (1) KR20070116060A (no)
CN (1) CN101166730A (no)
AU (1) AU2006218661A1 (no)
BR (1) BRPI0607404A2 (no)
CA (1) CA2599688A1 (no)
CR (1) CR9318A (no)
IL (1) IL185269A0 (no)
MX (1) MX2007010572A (no)
NI (1) NI200700223A (no)
NO (1) NO20074277L (no)
RU (1) RU2007131400A (no)
WO (1) WO2006094034A1 (no)
ZA (1) ZA200707525B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080009203A (ko) 2005-05-10 2008-01-25 라보라뚜와르 푸르니에 에스.아. 리버 엑스 리셉터 어고니스트의 신규한 용도
WO2008036238A2 (en) * 2006-09-19 2008-03-27 Wyeth Use of lxr modulators for the prevention and treatment of skin aging
CN101547688A (zh) * 2006-09-19 2009-09-30 惠氏公司 Lxr激动剂用于治疗骨关节炎的用途
AU2008345687A1 (en) * 2007-12-21 2009-07-09 Wyeth Llc Pyrazolo [1,5-a] pyrimidine compounds
EP3626309B1 (en) 2012-08-13 2023-03-08 The Rockefeller University Lxrbeta agonist for the treatment of cancer
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
AU2018373028A1 (en) 2017-11-21 2020-04-30 Inspirna, Inc. Polymorphs and uses thereof
WO2021119397A1 (en) 2019-12-13 2021-06-17 Rgenix, Inc. Metal salts and uses thereof
TWI773602B (zh) * 2021-11-29 2022-08-01 國立陽明交通大學 三芳基噌啉鹽化合物及其製造方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE35662B1 (en) 1970-10-16 1976-04-14 Ici Ltd Pharmaceutical compositions
GB1474399A (en) 1974-08-19 1977-05-25 Ici Ltd Cinnolin-3-yl carboxylic acids and derivatives thereof
FR2528838B1 (fr) * 1982-06-16 1985-10-11 Lipha Phenyl-5 benzodiazepines-1,3, procedes de preparation et intermediaires
MX9200299A (es) 1991-02-07 1992-12-01 Roussel Uclaf Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
DK0498722T3 (da) * 1991-02-07 1998-03-09 Roussel Uclaf Nye bicycliske nitrogenforbindelser substitueret med en benzylgruppe, fremgangsmåde til deres fremstilling, de opnåede nye intermediærer, deres anvendelse som lægemidler og de pharmaceutiske præparater som de indgår i
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5500427A (en) 1992-09-14 1996-03-19 Takeda Chemical Industries, Ltd. Cyclic compounds and their use
IL110172A (en) 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
GB9420557D0 (en) 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
DE69635254T2 (de) 1995-07-07 2006-07-13 Astrazeneca Ab Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten
JPH11514361A (ja) 1995-10-16 1999-12-07 藤沢薬品工業株式会社 Ｈ＋−ＡＴＰａｓｅとしての複素環式化合物
WO1998014431A1 (en) * 1996-10-01 1998-04-09 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
JPH10310579A (ja) 1997-03-11 1998-11-24 Sumitomo Chem Co Ltd ４−シアノシンノリンおよびその製造法
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
CA2367116A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
WO2001034609A1 (de) 1999-11-10 2001-05-17 Optische Werke G. Rodenstock Heterocyclisch annellierte indenochromenderivate
AU4738101A (en) 2000-03-17 2001-10-03 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
WO2002012228A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Cinnoline compounds
ATE364385T1 (de) 2000-10-12 2007-07-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
US20050010048A1 (en) 2000-10-12 2005-01-13 Linghang Zhuang Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
FR2817256B1 (fr) 2000-11-27 2005-07-15 Univ Pasteur Derives de l'acides 4-hydroxybutanoique et de son homologue superieur comme ligands des recepteurs du gamma- hydroxybutyrate (ghb), compositions pharmaceutiques les contenant et utilisations pharmaceutiques
EP1408986B1 (en) 2001-05-08 2008-09-24 Yale University Proteomimetic compounds and methods
EP1270535A3 (de) 2001-06-20 2004-02-18 Clariant GmbH Verfahren zur Herstellung von substituierten aromatischen Verbindungen
US6632810B2 (en) 2001-06-29 2003-10-14 Kowa Co., Ltd. Cyclic diamine compound with condensed-ring groups
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
PL371587A1 (en) 2002-01-17 2005-06-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
CN1628109A (zh) 2002-02-05 2005-06-15 诺沃挪第克公司 新颖的芳基－与杂芳基－哌嗪
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
AU2003213185A1 (en) 2002-02-22 2003-09-09 Pharmacia And Upjohn Company Arylsulfone derivatives
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
FR2842524B1 (fr) * 2002-07-16 2005-04-22 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
FR2842526B1 (fr) * 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
WO2004072042A2 (en) 2003-02-12 2004-08-26 Carex S.A. Quinoline derivative and their use for modulation of lxr activity
FR2856062B1 (fr) * 2003-06-12 2005-11-11 Aventis Pharma Sa Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
BRPI0416852A (pt) * 2003-11-21 2007-02-27 Array Biopharma Inc inibidores da quinase akt
CA2573745A1 (en) * 2004-07-21 2007-01-12 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
MX2007002592A (es) 2004-09-03 2007-10-10 Memory Pharm Corp Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos.
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds

Also Published As

Publication number Publication date
WO2006094034A1 (en) 2006-09-08
KR20070116060A (ko) 2007-12-06
US7700595B2 (en) 2010-04-20
CR9318A (es) 2007-10-23
EP1853566A1 (en) 2007-11-14
AU2006218661A1 (en) 2006-09-08
JP2008531709A (ja) 2008-08-14
IL185269A0 (en) 2008-02-09
ZA200707525B (en) 2009-07-29
MX2007010572A (es) 2007-10-04
CN101166730A (zh) 2008-04-23
NI200700223A (es) 2008-07-03
RU2007131400A (ru) 2009-04-10
US20060252757A1 (en) 2006-11-09
BRPI0607404A2 (pt) 2009-09-01
CA2599688A1 (en) 2006-09-08

Similar Documents

Publication Publication Date Title
NO20074277L (no) Kinnolinforbindelser og anvendelse derav som lever X reseptor modulatorer
ATE473744T1 (de) Modifizierte pyrimidin-glucocorticoid-rezeptor- modulatoren
DK2060570T3 (da) Som modulatorer af dopamin-d3-receptorer anvendelige azabicyclo(3.1.0)hexanderivater
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
MX2009003942A (es) Compuestos de quinolina.
WO2008042571A3 (en) Substituted indole compounds
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
CR20150088A (es) Anticuerpos anti-notch1 nrr
WO2009082437A3 (en) Selective androgen receptor modulators (sarms) and uses thereof
CY1110491T1 (el) Διαμορφωτες του υποδοχεα γλυκοκορτικοειδους αζαδεκαλινης
NO20074002L (no) Androgen reseptor-modulatorforbindelser og fremgangsmater
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
EA201300338A1 (ru) Пестицидная и паразитицидная смесь и композиция, которая включает новую кристаллическую модификацию фипронила
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
CR10280A (es) Anticuerpos de la efgl7 y metodos de uso
NO20073369L (no) Modulatorer av muskarinreseptorer
NO20075140L (no) Fremgangsmater og preparater for modulering av vaskulaer integritet
DE602006006369D1 (de) Entwicklerzusammensetzungen
NO20091771L (no) Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat
WO2007075884A3 (en) Androgen receptor modulator compounds and methods
EA200970189A1 (ru) Пирролидинонанилины как модуляторы прогестероновых рецепторов
ATE417816T1 (de) Anilinohexafluoroisopropanol verbindungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application